6 February 2026 · 3 min read
From Observation to Action: Why We Founded BioPhotonix
As an optometrist and orthoptist, the hardest part of a dry AMD diagnosis was never the diagnosis. It was the conversation that followed.
Read the articleNews and insights
From the front line of retinal care.
Articles from the BioPhotonix team on the science, the regulation and the business of treating dry AMD in the community.
6 February 2026 · 3 min read
Safety Without Compromise: Building a Regulatory-First Medical Company
There is a clear line between consumer wellness gadgets and regulated medical devices. We have chosen our side of it with absolute clarity.
Read the article6 February 2026 · 3 min read
The Silent Epidemic: Addressing the Unmet Need in Dry AMD
Around 200 million people live with AMD today, and 85 to 90% of them have the dry form. For decades the innovation has gone to the other 10%.
Read the article31 December 2025 · 3 min read
Turning Science into Solutions: Our Journey from Concept to Prototype
We have moved beyond proof of concept and into advanced prototype development. Here is how we are turning our vision into a medical reality.
Read the article